Prolonged PEG-IFN and RBV Is Effective in Patients with HCV Genotype 1 and High Viral Load Who Achieved Virological Response Later than 24 Weeks
Taisuke Ueda(Kindai University), Kazuomi Ueshima(Kindai University), Satoru Hagiwara(Kindai University Hospital), Hobyung Chung(Kindai University), Masatoshi Kudo(Kindai University), Sousuke Hayaishi(Kindai University), Tatsuo Inoue, Emi Ishikawa(Kyowa Chemical Industry (Japan)), Norihisa Yada(Kindai University), Yasunori Minami, Chie Tatsumi(Kindai University)
Cited by 3
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k